Cargando…
Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step
Throughout the past years we stepwise modified our immunosuppressive treatment regimen for patients with antibody-mediated rejection (ABMR). Here, we describe three consecutive groups treated with different regimens. From 2005 until 2008, we treated all patients with biopsy-proven ABMR with rituxima...
Autores principales: | Lachmann, Nils, Duerr, Michael, Schönemann, Constanze, Pruß, Axel, Budde, Klemens, Waiser, Johannes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306998/ https://www.ncbi.nlm.nih.gov/pubmed/28255562 http://dx.doi.org/10.1155/2017/6872046 |
Ejemplares similares
-
Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
por: Waiser, Johannes, et al.
Publicado: (2016) -
Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
por: Eskandary, Farsad, et al.
Publicado: (2019) -
The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection
por: Akagun, Tulin, et al.
Publicado: (2016) -
Poor Long-Term Renal Allograft Survival in Patients with Chronic Antibody-Mediated Rejection, Irrespective of Treatment—A Single Center Retrospective Study
por: Wu, Kaiyin, et al.
Publicado: (2021) -
Acute antibody-mediated renal allograft rejection associated with HLA-Cw17 antibody
por: Suneja, Manish, et al.
Publicado: (2012)